Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317294057> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2317294057 abstract "Hepatic arteries in cirrhosis show neoangiogenesis and vasodilatation, the latter mainly as a consequence of increased nitric oxide (Zipprich et al.JHep;49: 739). It remains unclear, when these pathological changes occur during the natural history of cirrhosis, i.e. in compensated or decompensated cirrhosis, and if the multikinase-inhibitor Sorafenib has an inhibitory effect. The aim of the study was to investigate 1)the differences of nitric oxide production in different stages of cirrhosis and 2)the influence of long-time treatment with Sorafenib on the hepatic artery in CCl4-cirrhotic rats. Methods: Cirrhosis was induced by CCl4 administration for 8 (compensated cirrhosis [CC]) and 12 weeks (decompensated cirrhosis [DC]) in the presence or absence of Sorafenib (5mg/kg bw per day). Bivascular liver perfusions were performed. Dose-response curves to the alpha1-receptor agonist methoxamine were obtained in the absence or presence of the nitric oxide synthetase inhibitor L-NMMA (10–4 M). Results: Basal perfusion pressure was significantly lower in DC (p<0.05) compared with Sorafenib-treated DC. In contrast, basal perfusion pressure was similar in CC and Sorafenib-treated CC suggesting, that an increase of neangiogenesis is only typical for DC. Dose-response curves to methoxamine, too, were significantly different in DC (p=0.019 vs. control) compared with Sorafenib-treated DC (n.s. vs. control), while CC and Sorafenib-treated CC did not show any difference. The presence of L-NMMA corrected the response in DC to a level of Sorafenib-treated DC. Therefore, nitric oxide production is increased in DC but not in CC and can be decreased by long-time Sorafenib treatment. Conclusion: Neoangiogenesis and increased nitric oxide production of the hepatic artery appear to be associated with advanced liver disease and decompensated cirrhosis. Treatment with Sorafenib might be a new therapeutic strategy to reduce neoangiogenesis and nitric oxide production of the hepatic artery." @default.
- W2317294057 created "2016-06-24" @default.
- W2317294057 creator A5021152840 @default.
- W2317294057 creator A5034454114 @default.
- W2317294057 creator A5048916978 @default.
- W2317294057 creator A5063647828 @default.
- W2317294057 creator A5071284274 @default.
- W2317294057 date "2011-01-01" @default.
- W2317294057 modified "2023-09-26" @default.
- W2317294057 title "Neoangiogenesis and nitric oxide is increased in hepatic arteries of decompensated but not compensated CCl4-cirrhotic rats, a process that can be blocked by Sorafenib" @default.
- W2317294057 doi "https://doi.org/10.1055/s-0030-1269514" @default.
- W2317294057 hasPublicationYear "2011" @default.
- W2317294057 type Work @default.
- W2317294057 sameAs 2317294057 @default.
- W2317294057 citedByCount "0" @default.
- W2317294057 crossrefType "journal-article" @default.
- W2317294057 hasAuthorship W2317294057A5021152840 @default.
- W2317294057 hasAuthorship W2317294057A5034454114 @default.
- W2317294057 hasAuthorship W2317294057A5048916978 @default.
- W2317294057 hasAuthorship W2317294057A5063647828 @default.
- W2317294057 hasAuthorship W2317294057A5071284274 @default.
- W2317294057 hasConcept C102124568 @default.
- W2317294057 hasConcept C126322002 @default.
- W2317294057 hasConcept C134018914 @default.
- W2317294057 hasConcept C170493617 @default.
- W2317294057 hasConcept C178790620 @default.
- W2317294057 hasConcept C185592680 @default.
- W2317294057 hasConcept C2777214474 @default.
- W2317294057 hasConcept C2777359374 @default.
- W2317294057 hasConcept C2778019345 @default.
- W2317294057 hasConcept C2778695046 @default.
- W2317294057 hasConcept C2778938600 @default.
- W2317294057 hasConcept C2780745239 @default.
- W2317294057 hasConcept C519581460 @default.
- W2317294057 hasConcept C71924100 @default.
- W2317294057 hasConceptScore W2317294057C102124568 @default.
- W2317294057 hasConceptScore W2317294057C126322002 @default.
- W2317294057 hasConceptScore W2317294057C134018914 @default.
- W2317294057 hasConceptScore W2317294057C170493617 @default.
- W2317294057 hasConceptScore W2317294057C178790620 @default.
- W2317294057 hasConceptScore W2317294057C185592680 @default.
- W2317294057 hasConceptScore W2317294057C2777214474 @default.
- W2317294057 hasConceptScore W2317294057C2777359374 @default.
- W2317294057 hasConceptScore W2317294057C2778019345 @default.
- W2317294057 hasConceptScore W2317294057C2778695046 @default.
- W2317294057 hasConceptScore W2317294057C2778938600 @default.
- W2317294057 hasConceptScore W2317294057C2780745239 @default.
- W2317294057 hasConceptScore W2317294057C519581460 @default.
- W2317294057 hasConceptScore W2317294057C71924100 @default.
- W2317294057 hasIssue "01" @default.
- W2317294057 hasLocation W23172940571 @default.
- W2317294057 hasOpenAccess W2317294057 @default.
- W2317294057 hasPrimaryLocation W23172940571 @default.
- W2317294057 hasRelatedWork W1965781866 @default.
- W2317294057 hasRelatedWork W1992842231 @default.
- W2317294057 hasRelatedWork W2027913950 @default.
- W2317294057 hasRelatedWork W2050423574 @default.
- W2317294057 hasRelatedWork W2058205365 @default.
- W2317294057 hasRelatedWork W2101411396 @default.
- W2317294057 hasRelatedWork W2163966674 @default.
- W2317294057 hasRelatedWork W2165958118 @default.
- W2317294057 hasRelatedWork W2398697207 @default.
- W2317294057 hasRelatedWork W2748952813 @default.
- W2317294057 hasVolume "49" @default.
- W2317294057 isParatext "false" @default.
- W2317294057 isRetracted "false" @default.
- W2317294057 magId "2317294057" @default.
- W2317294057 workType "article" @default.